Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

PARP inhibitor

- PMLiVE

Novo Nordisk becomes diabetes drug sales leader

Supplants former frontrunner Sanofi - but both firms set for a tough 2015

Senior AstraZeneca exec jumps ship to small biotech

Briggs Morrison unexpectedly leaves the UK firm

- PMLiVE

Sanofi will resubmit Lyxumia for FDA approval in Q3

Follows the GLP-1 agonist's all-clear by ELIXA cardiovascular safety study

- PMLiVE

Merck & Co’s diabetes drug Januvia cleared by CV safety trial

Concerns over the DPP-4 inhibitor 'put to bed' by TECOS cardiovascular trial

Roche Basel Switzerland

Roche maintains dominance as leading cancer drugmaker

But the firm’s growth is stalling as pricing pressures hit sales

- PMLiVE

AZ and BMS earn ASCO plaudits

Both firms tout new combination therapies at the annual cancer congress in Chicago

- PMLiVE

AZ escapes censure over cancer tweet

Firm did not breach UK’s Code of Practice over survival statistics post

- PMLiVE

AstraZeneca earmarks $285m for Swedish biologics expansion

Expectsnew Södertälje manufacturing plant to be up and running by 2019

- PMLiVE

Allergy specialist Circassia buys asthma firms

British-based company acquires Sweden’s Aerocrine and privately held Prosonix

- PMLiVE

Heart drug sales continue downward spiral

But revenue has stabilised after a tough three years of patent expiries

- PMLiVE

Payment to docs rules ‘an opportunity for pharma’

The industry’s reputation can be boosted by openness, say pharma compliance leaders

- PMLiVE

Pfizer breast cancer drug shines in latest trial

Study with Ibrance stopped early because of its success

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links